contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


invitation-to-presentation-of-bicos-q3-results-2022

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

BICO Group operates in the biotechnology industry and focuses on the development and manufacturing of technologies for cell-based research and medical development. The company's products are aimed at researchers and pharmaceutical companies. The business is global with a main presence in Europe, North America and Asia. BICO Group was founded in 2016 and is headquartered in Gothenburg, Sweden.

BICO Group

BICO’s interim report for the third quarter that ended on September 30, 2022, will be published in English and Swedish on Wednesday November 9, 2022, at 07:00 am CEST.Following the release of...

<div class="mfn-preamble"><p><strong>BICO’s interim report for the third quarter that ended on September 30, 2022, will be published in English and Swedish on Wednesday November 9, 2022, at 07:00 am CEST.</strong></p></div><div class="mfn-body"><p>Following the release of the report, a combined presentation webcast and telephone conference with the opportunity to ask questions will be held in English at 09:00 am CEST on the same day, with President &amp; CEO Erik Gatenholm and Interim CFO Mikael Engblom presenting the report.</p><p><strong>The presentation will be accessible via the following link:</strong><br>Webcast, at 09:00 am CEST:<br><a rel="nofollow noopener" href="https://urldefense.com/v3/__https:/ir.financialhearings.com/bico-q3-2022__;!!C05lT65P!xsITQVgdC5x9VPmk53hz-LopGGOJGrrfqKH1WS8DvWi21UgE7hN4lG8Zzx10WswV5BhKzOAlCPSFbbKF-OlvzmNDXQ$">https://ir.financialhearings.com/bico-q3-2022</a></p><p>To participate via telephone, please call any of the following numbers:<br>SE: +46 8&nbsp;505 16 386<br>UK: +44&nbsp;203&nbsp;198 48 84<br>US: +1&nbsp;412&nbsp;317 6300</p><p>Pin: 6705948#</p><p>The presentation will also be available on the company’s website:<br>&nbsp;<a rel="nofollow noopener" href="https://bico.com/investors/financials/financial-reports-and-presentations/">https://bico.com/investors/financials/financial-reports-and-presentations/</a></p></div><div class="mfn-footer mfn-8f1d0373e24d"><p><strong class="mfn-heading-1">For further information, please contact:</strong><br>Åsa Hillsten, SVP &amp; Head of Investor Relations, BICO Group AB<br>Phone: +46 70-081 81 17<br>Email:&nbsp;<a rel="nofollow noopener" href="mailto:ash@bico.com">ash@bico.com</a></p><p>This information was submitted for publication, through the agency of the contact persons set out above, on October 26, 2022, at 07:00 (CEST).</p></div><div class="mfn-footer mfn-about mfn-e8089670866c"><p><strong class="mfn-heading-1">About BICO</strong><br>Founded in 2016, BICO (formerly CELLINK) is the world’s leading bioconvergence company,&nbsp; with three business areas: Biosciences, Bioautomation, and Bioprinting. BICO reduces the organ shortage and speeds up drug development by providing accessible life science solutions that combine biology and technology, fundamentally shifting the global healthcare industry.<br>Using a combination of robotics, artificial intelligence, advanced genomics, and 3D bioprinting, our innovative technologies enable researchers and practitioners in the life sciences to conduct cell line development in 3D, perform high-throughput drug screening and diagnostics, and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. BICO is the future of life-saving treatments, as we enable our customers to improve people's health and lives.&nbsp;<br>Our products are trusted by more than 3,500 laboratories, including the top 20 pharmaceutical companies. We have more than 32,000 instruments in the field in over 65 countries and have been cited in over 11,000 publications. BICO is listed on Nasdaq Stockholm under BICO.&nbsp;<a rel="nofollow noopener" href="http://www.bico.com/">www.bico.com</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="nofollow noopener" href="https://storage.mfn.se/ffaa9300-352c-41b5-adf9-929a32220117/invitation-to-presentation-of-bicos-q3-results-2022.pdf" class="mfn-generated mfn-primary">Invitation to presentation of BICO’s Q3 results 2022</a></p></div>